Annual
Report
Tulip BioMed’s strength in innovation and product development is not only good news for doctors, but a valuable opportunity for investors. Publicly traded as OTC:TPBD, Tulip BioMed shows exceptional promise and is receiving a positive reception within the medical instrumentation market. Based on this positive outlook, we have already raised over $1 million
Under the premise that living tissue management will play a critical role in the future of surgical medicine, investors understand that we are able to leverage the Tulip legacy of quality and performance to build safer and better disposable instruments that cater to this market. Capitalizing on our existing reputation in cosmetic and plastic surgery, and looking to extend it to burgeoning areas such as stem cell procedures, Tulip BioMed is an attractive target for greater investment.
While specific revenue projections cannot be disclosed without a non-disclosure agreement, a glimpse at Tulip BioMed’s market potential is quite telling. With 57 of the top U.S. medical device companies having combined annual revenues of over $77 billion, occupying even a small portion of market share means big revenues. Our initial target markets and expected level of penetration over the next five years are listed below:
- Plastic and cosmetic market potential = $250 million
- Urinary incontinence market potential = $106 million
- Fine needle aspiration biopsy market potential = $468 million
- Orthopedic surgery procedures market potential = $36 million
- Stem cell research and regenerative therapy – still a developing market, with future potential estimated to be $1 billion plus.
For more information about investment opportunities with Tulip BioMed, please contact us at
619-298-6800 or investor@tulipbiomed.com.
|
